对患有复发性2级质瘤的患者进行脉冲降低剂量率再辐射
Colin M Harari1, Adam R Burr1, Brett A Morris1
1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, Wisconsin, USA.
Neuro-oncology advances
|June 7, 2024
概括
脉冲降低剂量率 (PRDR) 辐射显示出有希望的存活率和可接受的毒性,用于复发的2级质瘤. 选择了维持2级组织学水平的患者,在重新照射后经历了延长的生存期.
科学领域:
- 神经瘤学神经瘤学
- 辐射瘤学 辐射瘤学
- 临床结果研究研究
背景情况:
- 2级质瘤患者的存活率有变化,再辐射数据有限.
- 脉冲降低剂量率 (PRDR) 辐射正在研究复发的2级质瘤.
- 有限的成熟的临床数据存在于这个患者群体的再辐射.
研究的目的:
- 报告PRDR辐射治疗复发2级质瘤的治疗结果.
- 为了评估患者接受PRDR治疗复发性质瘤的生存和预后因素.
- 使用PRDR评估再辐射的疗效和安全性.
主要方法:
- 在2000年至2021年期间,对58名接受PRDR治疗的患者进行了回顾性分析.
- 辐射在0.2 Gy脉冲每3分钟进行一次.
- 使用卡普兰-梅尔和考克斯回归分析的生存结果.
主要成果:
- 首次手术后的平均存活时间为8.6年.
- 69%的患者转化为3级或4级质瘤.
- 在PRDR后的总生存期为12.6个月;无进展的生存期为6.2个月.
- 36%的整体应答率;选择的2级患者的存活率>5年.
结论:
- 这是使用PRDR治疗的最大的一系列复发性2级质瘤.
- PRDR显示出有希望的生存率和可接受的毒性,用于重新辐射.
- 1p19q代选择,KPS和从诊断到PRDR的时间预测了更好的生存率.
更多相关视频
10:48PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
9.5K
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
2.8K
相关概念视频
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Tumor Immunotherapy
2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
Varicose Veins II: Diagnostic Studies and Interprofessional Care
325
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
325
